



Cite this: *Chem. Commun.*, 2016, 52, 1945

Received 16th September 2015,  
Accepted 2nd December 2015

DOI: 10.1039/c5cc07772a

www.rsc.org/chemcomm

# Conversion of a non-heme iron-dependent sulfoxide synthase into a thiol dioxygenase by a single point mutation†


Kristina V. Goncharenko and Florian P. Seebeck\*

**EgtB from *Mycobacterium thermoresistibile* catalyzes O<sub>2</sub>-dependent sulfur–carbon bond formation between the side chains of *N*α-trimethyl histidine and γ-glutamyl cysteine as a central step in ergothioneine biosynthesis. A single point mutation converts this enzyme into a γ-glutamyl cysteine dioxygenase with an efficiency that rivals naturally evolved thiol dioxygenases.**

Non-heme iron oxygenases catalyze a broad range of chemically difficult reactions and therefore provide intriguing starting points to develop novel enzymes for industrial applications. Despite remarkable progress in mechanistic enzymology,<sup>1–7</sup> only few design studies describing modified non-heme iron enzymes with engineered activities<sup>8–12</sup> have explored this potential for technological innovation so far. As a further step into this nascent field of enzyme engineering we present an example of a monooxygenase that was converted into an efficient thiol dioxygenase based on minimal active site redesign.<sup>13</sup>

The sulfoxide synthase (EC 1.14.99.50) EgtB catalyzes the central step in ergothioneine biosynthesis (1, Fig. 1).<sup>14–16</sup> EgtB mediates carbon–sulfur bond formation between γ-glutamyl cysteine (γGC) and the imidazole ring of *N*α-trimethylated histidine (TMH). Concomitant oxidation of the bridging sulfur atom (2, Fig. 1) makes the overall reaction a four-electron oxidation, and classifies EgtB as a monooxygenase.<sup>17</sup> The active site of EgtB contains ferrous iron coordinated by a 3-His facial triad, the thiolate side chain of γGC and the imidazole ring of TMH (Fig. 2).<sup>16</sup> In this structure the likely O<sub>2</sub>-binding site is occupied by a water molecule or a hydroxide that also hydrogen bonds to the side chain of Gln55 (2.8 Å), a neighbouring water molecule (3.1 Å) and the side chain a Tyr377 (2.8 Å). In this report we show that substitution of Tyr377 to Phe completely changes the catalytic activity of EgtB.

The variant enzyme (EgtB<sub>Y377F</sub>) catalyzes dioxygenation of γGC with an efficiency similar to that of naturally evolved



**Fig. 1** Top: EgtB<sub>wt</sub> catalyzes oxidative C–S bond formation between γ-glutamyl cysteine and *N*α-trimethyl histidine (TMH) to form **2**. This sulfoxide is the central intermediate in the biosynthesis of ergothioneine (**1**). EgtB<sub>Y377F</sub> catalyzes the formation of γGC dioxide (**4**) mimicking naturally evolved cysteine dioxygenases (CDO) which produce cysteine sulfinic acid (**3**).


cysteine dioxygenases (CDO, EC 1.13.11.20).<sup>18,19</sup> CDOs also bind ferrous iron by a 3-His facial triad combined with the thiolate and amine ligands from the substrate (Fig. 2), but the overall structures of EgtB and CDO are unrelated. A wealth of structural, biochemical, spectroscopic and computational investigations suggest that CDO catalysed formation of cysteine sulfinic acid (**3**) goes through a cysteine bound iron(III)–superoxo species (a, Fig. 2), followed by intermediates b and c.<sup>18–26</sup> The structural and functional similarities between the active sites of CDO and EgtB raise the possibility that thiol dioxygenation and sulfoxide synthesis may proceed through at least one common catalytic intermediate.

The following kinetic analysis of EgtB<sub>wt</sub> and EgtB<sub>Y377F</sub> indicates that an iron(III)–superoxo species (A, a) may be this common intermediate.

Department for Chemistry, University of Basel, St. Johannis-Ring 19, 4056, Basel, Switzerland. E-mail: florian.seebeck@unibas.ch

† Electronic supplementary information (ESI) available: Fig. S1–S13, and detailed experimental procedures. See DOI: 10.1039/c5cc07772a





**Fig. 2** Top: Active site of EgtB from *M. thermoresistibile* in complex with Mn(II) (magenta sphere), TMH and  $\gamma$ GC (PDB code 4X8D).<sup>16</sup> One plausible catalytic mechanism has been proposed for EgtB<sub>wt</sub>: the substrate bound complex reacts with O<sub>2</sub> to form an iron(III)–superoxo species (A). Protonation by Tyr377 and reduction by one-electron transfer from  $\gamma$ GC leads to the iron(III)–hydroperoxo species (B). C–S bond formation between the  $\gamma$ GC radical and TMH (C), deprotonation by Tyr377 and stereospecific sulfoxidation of D to the S-sulfoxide **2** concludes the catalytic cycle. Gray: in the absence of an acidic residue at position 377 species A predominantly reacts to B' which reacts further to  $\gamma$ GC dioxide (**4**) potentially through a CDO-like mechanism. Bottom: Active site of murine CDO in complex with cysteine (PDB code 4IEW).<sup>27</sup> The consensus mechanism of CDO proceeds via a cysteine bond iron(III)–superoxo species (a), followed by irreversible S–O bond formation (b), homolytic O–O bond scission (c), and radical rebound to form cysteine sulfinic acid (**3**).<sup>18–26</sup>

To conduct this study we produced EgtB<sub>wt</sub> and EgtB<sub>Y377F</sub> in *Escherichia coli*, and we monitored the rate of enzyme catalyzed sulfoxide (**2**) production using a published HPLC-based assay.<sup>16</sup> Michaelis–Menten analysis of this data revealed 10<sup>3</sup>-fold less sulfoxide synthase activity for EgtB<sub>Y377F</sub> than for EgtB<sub>wt</sub>. This reduction is entirely due to a smaller  $k_{\text{cat}}$ , since  $K_{\text{M, TMH}}$  remained unchanged (Table 1, Fig. S1 and S2, ESI†). We also determined the substrate kinetic isotope effect (KIE) using C<sub>2</sub>-deuterated TMH. Because both enzymes showed a substrate KIE near unity (Fig. S3, ESI†) we concluded that C<sub>2</sub>–H bond cleavage is not rate limiting in either enzyme and that hydrogen or proton removal from TMH is not an essential function of Tyr377.

When we compared the rates of  $\gamma$ GC consumption and sulfoxide production (Fig. S4, ESI†) we found a rather surprising difference between the two enzymes. In EgtB<sub>wt</sub> catalyzed reactions substrate

consumption ( $k_{\gamma\text{GC, wt}} = 0.4 \pm 0.02 \text{ s}^{-1}$ ) and sulfoxide formation ( $k_{\text{sulfoxide, wt}} = 0.3 \pm 0.06 \text{ s}^{-1}$ ) were essentially coupled. By contrast, in EgtB<sub>Y377F</sub> catalyzed reactions,  $\gamma$ GC consumption was much faster ( $k_{\gamma\text{GC, Y377F}} = 0.6 \pm 0.1 \text{ s}^{-1}$ ) than sulfoxide production ( $k_{\text{sulfoxide, Y377F}} = 0.002 \text{ s}^{-1}$ ). NMR analysis of the completed reactions revealed that EgtB<sub>Y377F</sub> oxidizes most substrate to  $\gamma$ GC dioxide (**4**) instead (Fig. S5 and S6, ESI†). This new activity still depends on TMH, which indicates that dioxygenation proceeds via the same substrate complex as sulfoxide production. In the absence of TMH both EgtB<sub>wt</sub> and EgtB<sub>Y377F</sub> catalyzed  $\gamma$ GC dioxygenation at a similarly slow rate ( $k_{\gamma\text{GC}} = 0.008 \text{ s}^{-1}$ , Fig. S7 and S8, ESI†). Apparently, the single substrate complex is significantly less reactive and its reaction specificity is not influenced by residue 377.

We also determined the Michaelis–Menten parameters for EgtB<sub>Y377F</sub> catalyzed  $\gamma$ GC dioxygenation (Table 1). Considering that

**Table 1** Kinetic parameters of EgtB variants<sup>a</sup>

	pH	$k_{\text{cat}, \gamma\text{GC}} (\text{s}^{-1})$	$K_{\text{M}, \gamma\text{GC}} (\mu\text{M})$	$k_{\text{cat}}/K_{\text{M}} (\text{M}^{-1} \text{s}^{-1})$	$k_{\text{cat}, \text{TMH}} (\text{s}^{-1})$	$K_{\text{M}, \text{TMH}} (\mu\text{M})$	$k_{\text{cat}}/K_{\text{M}} (\text{M}^{-1} \text{s}^{-1})$
<b>Sulfoxide synthase</b>							
EgtB <sub>wt</sub>	8.0	$7.5 \times 10^{-1}$	27	$2.8 \times 10^4$	$8.5 \times 10^{-1}$	10	$7.4 \times 10^4$
EgtB <sub>Y377F</sub>	8.0	—	—	—	$0.9 \times 10^{-4}$	10	$8.5 \times 10^1$
EgtB <sub>wt</sub>	6.0	1.1	370	$2.0 \times 10^3$	$1.2 \times 10^0$	22	$5.7 \times 10^4$
EgtB <sub>Y377F</sub>	6.0	—	—	—	$3.2 \times 10^{-3}$	40	$8.0 \times 10^1$
<b><math>\gamma</math>GC dioxygenase</b>							
EgtB <sub>Y377F</sub>	8.0	1.2	110	$1.1 \times 10^4$	—	—	—
EgtB <sub>Y377F</sub>	6.0	0.9	320	$2.7 \times 10^3$	—	—	—
CDO <sub>murine</sub> <sup>19</sup>	7.5	1.8	700	$2.6 \times 10^4$	—	—	—

<sup>a</sup> Standard deviation correspond to less than 20% of averaged value. Apparent  $k_{\text{cat}}$  and  $k_{\text{cat}}/K_{\text{M}}$  in the presence co-substrate in a concentration at least 3-fold higher than the corresponding  $K_{\text{M}}$ .



this protein may never have evolved to catalyze this alternative reaction it is particularly striking that its catalytic efficiency closely matches that of naturally evolved CDOs (Table 1).

The kinetic parameters for EgtB<sub>Y377F</sub> catalyzed dioxygenation are also remarkably similar to those for EgtB<sub>wt</sub> catalyzed sulfoxide synthesis (Table 1). Given the similar apparent  $K_M$  in both enzymes for both substrates we have no indication that the substitution of residue 377 affected binding of TMH or  $\gamma$ GC. The fact that both enzymes oxidize  $\gamma$ GC at similar rates further suggest that the efficiency of O<sub>2</sub> binding and activation have not changed either. However, the resulting ternary complex (A, Fig. 2) does behave quite differently in the wild-type and variant protein.

In the presence of ascorbate EgtB<sub>wt</sub> and EgtB<sub>Y377F</sub> catalyze many hundreds of turnovers, without any sign of inactivation. Without ascorbate EgtB<sub>wt</sub> oxidizes to the inactive iron(III) form after approximately 100 turnovers,<sup>16</sup> corresponding to an autoxidation rate of  $k_{\text{autoxidation}} = 0.01 \text{ s}^{-1}$  (Fig. S9, ESI†). This inactivation is reversible by addition of ascorbate,<sup>28,29</sup> and is best explained by unproductive decay of the iron(III)–superoxo species A to superoxide and ferric EgtB.<sup>30–33</sup> EgtB<sub>Y377F</sub> inactivates 10-fold faster ( $k_{\text{autoxidation}} = 0.1 \text{ s}^{-1}$ , Fig. S10, ESI†), indicating that the initial iron coordinated oxygen species may be destabilized by the Tyr377 to Phe substitution (Fig. 2).

This substitution also influences the solvent KIE on EgtB. The sulfoxide synthase activity of EgtB<sub>wt</sub> and the  $\gamma$ GC dioxygenase activity of EgtB<sub>Y377F</sub> are both characterized by a solvent KIE near unity ( $1.2 \pm 0.2$  and  $0.9 \pm 0.1$ , Fig. S11 and S12, ESI†). In contrast, the sulfoxide synthase activity of EgtB<sub>Y377F</sub> exhibited a solvent KIE of  $1.9 \pm 0.1$  (Fig. S11, ESI†), indicating that one or multiple protons or hydrogen atoms are being transferred in the rate limiting step. Because the dioxygenase activity is not affected by solvent deuteration we conclude that this transfer occurs exclusively on sulfoxide synthase pathway. In the context of the proposed mechanisms for EgtB and CDO (Fig. 2) the most likely candidate for this solvent isotope sensitive step would be protonation of the iron(III)–superoxo intermediate A. Protonation of this oxygen species may be important to increase the thiyl radical character of the  $\gamma$ GC ligand (B), which in turn could attack the imidazole ring of TMH (C). In EgtB<sub>Y377F</sub> the iron coordinated superoxide is not protonated and may instead attack the electron deficient sulfur atom on  $\gamma$ GC (A to B'). The analogous S–O bond forming step (a to b) has been found as the first irreversible step in CDO catalyzed cysteine dioxygenation (Fig. 2).<sup>18–26</sup>

According to this model, species A can either react *via* irreversible proton transfer to intermediate B, or *via* irreversible S–O bond formation leading to intermediate B' simply depending on the availability of an acidic proton in the active site. We did indeed observe a 3.5-fold increase in  $k_{\text{cat}}$  for EgtB<sub>Y377F</sub> catalyzed sulfoxide synthesis when the reaction pH was lowered from 8.0 to 6.0 (Table 1). The observed sulfoxide synthase activity is a hyperbolic function of proton concentration with a half-saturation point ( $K_{M,\text{proton}}$ ) near pH 7 (Fig. S13, ESI†). This dependence is consistent with a general acid mechanism in which the phosphate buffer ( $\text{p}K_{a,\text{monoanion}} = 7.2$ ), or an alternative protein residue with a similar  $\text{p}K_a$  can replace Tyr377 as an indirect proton source. The  $k_{\text{cat}}$  of  $\gamma$ GC dioxygenase activity of

the same protein proved nearly constant in the same pH range (Table 1) which is in agreement with the proposition that acid catalysis is less important in the first irreversible step of thiol dioxygenation (A to B' or a to b').

In conclusion, we identified Tyr377 as a catalytic residue in EgtB from *M. thermoresistibile*. Mutation of this residue to Phe did not measurably affect substrate binding or O<sub>2</sub> activation, but instead changed the dominant activity of this enzyme. The remaining sulfoxide synthase activity of EgtB<sub>Y377F</sub> is characterized by an increased solvent KIE and significant dependence on buffer pH. These observations are best explained with a mechanistic model suggesting that (i) the sulfoxide synthase and the thiol dioxygenase reaction pathways share a common intermediate, (ii) that this intermediate is the iron(III)–superoxo species A, and (iii) that protonation by Tyr377 is essential to move this species towards sulfoxide synthesis, and away from  $\gamma$ GC dioxygenation. This report the first example of a non-heme iron enzyme which could be engineered to efficiently catalyze a completely different reaction type than the parent enzyme.

CDOs and EgtB belong to entirely unrelated protein families and evolved along different selective pressures. The fact that EgtB<sub>Y377F</sub> catalyzes thiol dioxygenation with similar efficiency as CDOs makes the two enzymes a stunning example of accidental convergent evolution. We anticipate that detailed comparison of the two catalyst will prove a fruitful avenue to advance our current understanding of both reaction types.<sup>18–26</sup>

K. V. G. is a recipient of a Swiss Government Fellowship for Excellence; F. P. S. is supported by the “Professur für Molekulare Bionik” and by an ERC starting grant.

## Notes and references

- 1 J. E. Baldwin and M. Bradley, *Chem. Rev.*, 1990, **90**, 1079–1088.
- 2 J. C. Price, E. W. Barr, T. E. Glass, C. Krebs and J. M. Bollinger Jr., *J. Am. Chem. Soc.*, 2003, **125**, 13008–13009.
- 3 M. Costas, M. P. Mehn, M. P. Jensen and L. Que Jr., *Chem. Rev.*, 2004, **104**, 939–986.
- 4 E. G. Kovaleva and J. D. Lipscomb, *Nat. Chem. Biol.*, 2008, **4**, 186–193.
- 5 W. A. van der Donk, C. Krebs and J. M. Bollinger Jr., *Curr. Opin. Struct. Biol.*, 2010, **20**, 1–11.
- 6 M. M. Mbughuni, M. Chakrabarti, J. A. Hayden, E. L. Bominaar, M. P. Hendrich, E. Münck and J. D. Lipscomb, *Proc. Natl. Acad. Sci. U. S. A.*, 2010, **107**, 16788–16793.
- 7 K. Ray, F. F. Pfaff, B. Wang and W. Nam, *J. Am. Chem. Soc.*, 2014, **136**, 13942–13958.
- 8 S. L. Groce and J. D. Lipscomb, *J. Am. Chem. Soc.*, 2003, **125**, 11780–11781.
- 9 J. Schlosrich, K. L. Eley, P. J. Crowley and T. D. H. Bugg, *ChemBioChem*, 2006, **7**, 1899–1908.
- 10 S. M. Pratter, C. Konstantinovics, C. M. L. Giuro, E. Leitner, D. Kumar, S. P. de Visser, G. Grogan and G. D. Straganz, *Angew. Chem., Int. Ed.*, 2013, **52**, 9677–9681.
- 11 H. M. O'Hare, F. Huang, A. Holding, O. W. Choroba and J. B. Spencer, *FEBS Lett.*, 2006, **580**, 3445–3450.
- 12 M. Gunsior, J. Ravel, G. L. Challis and C. A. Townsend, *Biochemistry*, 2004, **43**, 663–674.
- 13 M. D. Toscano, K. J. Woycechowsky and D. Hilvert, *Angew. Chem., Int. Ed.*, 2007, **46**, 3212–3236.
- 14 Y. Ishikawa, S. E. Israel and D. B. Melville, *J. Biol. Chem.*, 1974, **249**, 4420–4427.
- 15 F. P. Seebeck, *J. Am. Chem. Soc.*, 2010, **132**, 6632–6633.
- 16 K. V. Goncharenko, A. Vit, W. Blankenfeldt and F. P. Seebeck, *Angew. Chem., Int. Ed.*, 2015, **54**, 2821–2824.



- 17 A. Vit, G. T. Mashabela, W. Blankenfeldt and F. P. Seebeck, *Chem-BioChem*, 2015, **16**, 1490–1496.
- 18 B. S. Pierce, J. D. Gardner, L. J. Bailey, T. C. Brunold and B. G. Fox, *Biochemistry*, 2007, **46**, 8569–8578.
- 19 W. Li and B. S. Pierce, *Arch. Biochem. Biophys.*, 2015, **565**, 49–56.
- 20 S. Aluri and S. P. de Visser, *J. Am. Chem. Soc.*, 2007, **129**, 14846–14847.
- 21 C. R. Simmons, K. Krishnamoorthy, S. L. Granett, D. J. Schuller, J. E. Dominy, T. P. Begley, M. H. Stipanuk and P. A. Karplus, *Biochemistry*, 2008, **47**, 11390–11392.
- 22 D. Kumar, W. Thiel and S. P. de Visser, *J. Am. Chem. Soc.*, 2011, **133**, 3869–3882.
- 23 J. A. Crawford, W. Li and B. S. Pierce, *Biochemistry*, 2011, **50**, 10241–10253.
- 24 E. Blaesi, J. D. Gardner, B. G. Fox and T. C. Brunold, *Biochemistry*, 2013, **52**, 6040–6051.
- 25 R. J. Souness, T. Kleffmann, E. P. Tchesnokov, S. M. Wilbanks, G. B. Jameson and G. N. Jameson, *Biochemistry*, 2013, **52**, 7606–7617.
- 26 E. J. Blaesi, B. G. Fox and T. C. Brunold, *Biochemistry*, 2014, **63**, 5759–5770.
- 27 C. M. Driggers, R. B. Cooley, B. Sankaran, L. L. Hirschberger, M. H. Stipanuk and P. A. Karplus, *J. Mol. Biol.*, 2013, **425**, 3121–3136.
- 28 G. T. Mashabela and F. P. Seebeck, *Chem. Commun.*, 2013, **49**, 7714–7716.
- 29 H. Song, M. Leninger, N. Lee and P. Liu, *Org. Lett.*, 2013, **15**, 4854–4857.
- 30 R. E. Brantley, S. J. Smerdon, A. J. Wilkinson, E. W. Singleton and J. S. Olson, *J. Biol. Chem.*, 1993, **268**, 6993–7010.
- 31 S. C. Trewick, T. F. Henshaw, R. P. Hausinger, T. Lindahl and B. Sedgwick, *Nature*, 2002, **419**, 174–178.
- 32 J. K. Crowell, W. Li and B. S. Pierce, *Biochemistry*, 2014, **53**, 7541–7548.
- 33 I. G. Denisov and S. G. Sligar, in *Cytochrome P450*, ed. P. R. Ortiz de Montellano, Springer International Publishing, Switzerland, 2015.

